BENZODIAZEPINES WITH SLOWER RATE OF ACTION MAY HAVE LESS ABUSE POTENTIAL; SCHEDULING FOR EXISTING BENZOS RULED APPROPRIATE BY FDA HEARING PARTICIPANTS
Slower acting benzodiazepines may have a lower abuse potential, John Roache, PhD, University of Texas, suggested at a Sept. 11 FDA public hearing on criteria for benzodiazepine scheduling in Washington, D.C. FDA convened a panel to examine whether data support differential scheduling of individual members of the benzodiazepine class, which have been collectively placed in Schedule IV since 1984.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth